<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159906">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02097394</url>
  </required_header>
  <id_info>
    <org_study_id>RJYYXHNK-002</org_study_id>
    <nct_id>NCT02097394</nct_id>
  </id_info>
  <brief_title>The Clinical Study on Combizym and Bifidobacteri to Prevent the Recurrence of Colon Polyps</brief_title>
  <official_title>A Randomized Controlled Study on Combizym and Bifidobacteria to Prevent the Recurrence of Colon Polyps</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is whether digestion enzyme(Combizym) and intestinal flora
      drugs(Bifidobacteria) can decease recurrence rate of colon polyps
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colon polyps has high recurrence rate in the digestion diseases. However, the reasons are
      not clear. The possible reasons for the recurrence of colon polyps include intestinal
      inflammation (e.g., Ulcerative colitis), intestinal flora imbalance (the benefit intestinal
      bacteria reduced, which lead to diarrhea or constipation), long-term indigestion. The
      investigators propose to examine whether digestion enzyme (Combizym) and intestinal flora
      drugs(Bifidobacteria) can decease recurrence rate of colon polyps
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>recurrence of colon polyps</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The whole patients need be examined by colonoscopy one year later. The recurrence rate of colon polyps will be acquired in different arms</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Combizym</condition>
  <condition>Bifidobacteri</condition>
  <condition>Colon Polyps</condition>
  <arm_group>
    <arm_group_label>Combizym</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These patients who have cutted colon polyps will eat the digestion enzyme(Combizym) regularly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bifidobacteri</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These patients who have cutted colon polyps will eat Bifidobacteri regularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combizym + Bifidobacteri</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These patients who have cutted colon polyps will eat drugs (Combizym + Bifidobacteri) regularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>these patients who have cutted colon polyps will not eat any drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combizym</intervention_name>
    <description>Combizym( 1 tablet, po, tid)</description>
    <arm_group_label>Combizym</arm_group_label>
    <other_name>Oryz-Aspergillus Enzyme And Pancreatin Tablet</other_name>
    <other_name>(produced by Nordmark Arzneimittel GmbH &amp; Co. KG)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bifidobacteri</intervention_name>
    <description>Bifidobacteri (2 tablet, po, tid)</description>
    <arm_group_label>Bifidobacteri</arm_group_label>
    <other_name>Live Combined Bifidobacterium，Lactobac and Enterococcus Capsules</other_name>
    <other_name>(produced by Shanghai XinYi Company)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combizym + Bifidobacteri</intervention_name>
    <description>Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)</description>
    <arm_group_label>Combizym + Bifidobacteri</arm_group_label>
    <other_name>Combizym(Oryz-Aspergillus Enzyme And Pancreatin Tablet)</other_name>
    <other_name>(produced by Nordmark Arzneimittel GmbH &amp; Co. KG)</other_name>
    <other_name>Bifidobacteri(Live Combined Bifidobacterium，Lactobac and Enterococcus Capsules)</other_name>
    <other_name>(produced by Shanghai XinYi Company)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control</intervention_name>
    <description>have no any drug</description>
    <arm_group_label>control</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients who have cutted colon polyps in one month, and the diagnosis were proved by
        pathological analysis

        Exclusion Criteria:

          -  have organic or other functional disease

          -  pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengliang Chen</last_name>
    <role>Study Director</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoqing Tian</last_name>
    <email>txqwl2004@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>July 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Shengliang Chen</investigator_full_name>
    <investigator_title>professor,chief physician</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colonic Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
